|Day Low/High||58.12 / 59.00|
|52 Wk Low/High||42.48 / 58.46|
I do think that this Fed Chair has learned to be cautious, in reflection of the policy errors made in late 2018.
Traders can learn from watching, as well as doing, and with the FOMC meeting landing, now's best time to practice the former.
These stocks are priced for total imperfection. That's just what you want.
The stocks of many companies anticipated a more stringent series of tariffs and we didn't get them.
The price of EL has corrected lower, and if its quarterly report or guidance is better than expected, we should the uptrend resume.
Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.
A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.
The aging population is creating a massive tailwind for companies that provide cutting-edge health care.
TheStreet's quants like the stock. What do the charts say?
Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.
Sure, Celgene, in its tie-up with Bristol-Myers Squibb, had to sell to meet merger requirements, but look at the future pay off for Amgen.
With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
Amgen's deal to buy Otezla from Celgene should not deter the drugmaker's stock from gaining ground over the long haul.
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
* Ignore slowing global economic growth at your own risk * Global debt will continue to serve as a governor to growth * Global debt has not been supported by growth in the global economy * Like the Potemkin Village, global debt growth has created an...
AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.
These stocks and sectors are safe havens, and may even be opportunities.
With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.
Here's the only way to explain why stocks jump like mad if the companies underneath them only perform slightly better than the analysts worried they would.
Equities are a bit higher across the board since our last update. Homebuilders continue to be in the green as 30-year mortgage rates hover near three-year lows. This is starting to have an effect as purchase application demand has posted its biggest...
And as the semiconductor sector continues to shine, Brooks Automation is a name to keep in mind.
Breaking down the impact on Facebook, Alphabet and Amazon of congressional hearings.
Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.
Watch the Russell 2000, housing activity, and mergers and acquisitions.
The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.